Trevi Therapeutics, Inc.
TRVI
$16.64
-$0.18-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.19M | 17.16M | 15.85M | 14.74M | 13.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.56M | 52.77M | 49.33M | 51.35M | 51.52M |
| Operating Income | -59.56M | -52.77M | -49.33M | -51.35M | -51.52M |
| Income Before Tax | -51.18M | -45.68M | -42.82M | -45.89M | -47.35M |
| Income Tax Expenses | -70.00K | -72.00K | -63.00K | -31.00K | -47.00K |
| Earnings from Continuing Operations | -51.11 | -45.61 | -42.76 | -45.86 | -47.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.11M | -45.61M | -42.76M | -45.86M | -47.30M |
| EBIT | -59.56M | -52.77M | -49.33M | -51.35M | -51.52M |
| EBITDA | -59.42M | -52.63M | -49.18M | -51.20M | -51.37M |
| EPS Basic | -0.34 | -0.32 | -0.32 | -0.37 | -0.42 |
| Normalized Basic EPS | -0.21 | -0.20 | -0.20 | -0.23 | -0.26 |
| EPS Diluted | -0.34 | -0.32 | -0.32 | -0.37 | -0.42 |
| Normalized Diluted EPS | -0.21 | -0.20 | -0.20 | -0.23 | -0.26 |
| Average Basic Shares Outstanding | 597.99M | 572.88M | 544.90M | 505.40M | 461.58M |
| Average Diluted Shares Outstanding | 597.99M | 572.88M | 544.90M | 505.40M | 461.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |